

Cascade Wittig reaction-double Claisen & Cope rearrangements: one-pot synthesis of diprenylated coumarins gravelliferone, balsamiferone and 6,8-diprenylumbelliferone


Rupesh E. Patre^{aψ}, Jyoti B. Shet^a, Perunninakulath S. Parameswaran^b and Santosh G. Tilve^{a*}

^aDepartment of Chemistry, Goa University, Taleigao Plateau, Goa 403 206, India.

^cNational Institute of Oceanography, Dona Paula, Goa 403 004, India.


Abstract—A cascade Wittig reaction-double Claisen & Cope rearrangements has been employed for a one-pot synthesis of diprenylated coumarins gravelliferone, balsamiferone & 6,8-diprenylumbelliferone from a common precursor 2,4-diprenyloxybenzaldehyde © 2009 Elsevier Science. All rights reserved

Cascade,¹ domino² or tandem³ reactions play an important role in the construction of complex molecular framework in fewer steps leading to saving time, cost and energy. In 2002, Schobert and Gordon reviewed domino Wittig and pericyclic reactions for bioactive heterocycles.^{4a} Taylor and Quesada reported a tandem Horner-Wadsworth-Emmons olefination/Claisen rearrangement/hydrolysis sequence.^{4b} In continuation of our interest in such reactions, we explored a Wittig reaction in combination with ene,^{5a} Diels-Alder,^{5b} electrocyclic,^{5c} oxidation^{5d} and reduction^{5e} reactions. Herein, we report one-pot synthesis of naturally occurring gravelliferone **1**, balsamiferone **2** and 6,8-diprenylumbelliferone **3** from 2,4-diprenyloxybenzaldehyde **4**, employing a cascade Wittig reaction, double Claisen & Cope rearrangements.



* Corresponding author: Tel.: 91-832-6519317; fax: +91-832-2452886; e-mail: stilve@unigoa.ac.in
ψ Present address: Syngenta Biosciences Pvt. Ltd. Santa Monica Works, Corlim, Ilhas, Goa 403 110

Coumarins are a group of an important class of abundant natural oxygen heterocycles having a wide range of biological activities⁶ such as anti-HIV, anti-tumor, anti-hypertension, anti-arrhythmia, anti-osteoporosis, pain relief, antisepsis as well as prevention of asthma. Several of these coumarins have prenyl side chains in their skeleton either intact or in a modified form as a furan or pyran ring.⁷ Gravelliferone 1 [3-(1,1'-dimethylallyl)-6-(3,3'-dimethyl allyl)-7-hydroxy coumarin] isolated⁸ from *R. graveolens*, balsamiferone, 2 [3,6-di-(3,3'-dimethylallyl)-7-hydroxy coumarin] isolated⁹ from *Amyris balsamifera*, and 6,8-diprenyllumbelliferone 3 isolated¹⁰ from Citrus species are three typical diprenylated coumarins.




Scheme 1 Synthetic plan for gravelliferone.

All the known synthetic routes¹¹ for the gravelliferone **1** employ single Claisen-Cope rearrangement for the introduction of a prenyl group in the pyran ring. Realizing the presence of two such prenyl groups in the skeleton, we speculated that if two consecutive Claisen-Cope rearrangements can occur, a concise route for **1** could be unfolded. Thus, 2'-prenyloxy group of the ethyl cinnamate **6** could undergo preferential Claisen-Cope rearrangement over 4'-prenyloxy group due to steric crowding during the formation of **1** via 7-prenyloxy-6-prenyl coumarin **8**, a well known intermediate¹¹ for the synthesis of gravelliferone (Scheme 1). Recently, Nicolaou *et al.* demonstrated two such consecutive Claisen rearrangements for the total synthesis of artochamins.¹²


To check the above hypothesis, the required 2,4-diprenyloxybenzaldehyde **4** was prepared from 2,4-dihydroxybenzaldehyde in a straight forward manner.^{13a} Initially, the Wittig reaction was carried out in refluxing diphenyl ether for 20 min. To our satisfaction, we could isolate **8** (30%) along with **6** (50%). After confirming the formation of **8**, we proceeded to the planned synthesis of **1** by extending the refluxing time in diphenyl ether for 4h. Purification of reaction products by flash chromatography,

provided 7-prenyloxy-3-prenyl coumarin **9** (2.5%), 8,9,9-trimethyl-6-(3-methylbut-2-enyl)-8,9-dihydro-*2H*-furo[2,3-*h*]chromen-2-one **10** (15%), 6,8-diprenylumbelliferone **3** (15%), balsamiferone **2** (5%),^{11c,14} gravelliferone **1** (10%), and demethylsuberosin **11** (20%) (Scheme 2).^{13b}



Scheme 2 Reagents and conditions: (a) $\text{Ph}_3\text{P}=\text{CHCOOEt}$ **5**, PhOPh , reflux.

The formation of gravelliferone **1** is rationalised by a postulated sequential Wittig reaction, the first Claisen rearrangement of 2'-prenyloxy group leading to **12** followed by 3,3-sigmatropic rearrangement (Cope rearrangement) *via* route **a** (Scheme 3) to form intermediate **7**, which on cyclisation forms pyran ring **8**. The second Claisen rearrangement of the 7'-prenyloxy coumarin **8** to form **13**, followed by two consecutive Cope rearrangements gives **1** *via* **14**. While **10** is formed by annulation of intermediate **13**, 3-prenyl-7-prenyloxy coumarin **9** may have arisen by Cope rearrangement product **15** (from **12**) getting cyclised (Scheme 3, route **b**). The balsamiferone¹⁴ **2** may have formed by prenylation of the deprenylated product demethylsuberosin **11** or from **9** *via* an intra/intermolecular pathway. Similarly, the natural product 6,8-diprenylumbelliferone **3** may have formed from direct prenylation of **11** or by intramolecular prenylation of **8** (Scheme 3).



Scheme 3 Postulated mechanism for the formation of **1**, **2**, **3** and **9**.

In conclusion, the present work successfully demonstrates utility of the cascade Wittig reaction, double Claisen and Cope rearrangements for the synthesis of naturally occurring coumarins gravelliferone **1**, balsamiferone **2**, and 6,8-diprenylumbelliferone **3** in a single step. This is the shortest route for the synthesis of gravelliferone **1** and balsamiferone **2** and the first report on the total synthesis of 6,8-diprenylumbelliferone **3**. Further studies to see the effect of introduction of group at 3-position of coumarin by using appropriate Wittig reagent on this double Claisen-Cope rearrangements and the possibility of cascade Wittig multiple Claisen-Cope rearrangements will be undertaken.

Acknowledgments

We thank IISc, Bangalore, for HRMS and CSIR, New Delhi, for financial support.

References and Notes

1. (a) Posner, G. H. *Chem. Rev.* **1986**, *I*, 831. (b) Jasperse, C. P.; Curran, D. P; Fevig ,T. L. *Chem. Rev.* **1991**, *91*, 1237. (c) Nicolaou, K. C.; Edmonds, D. J.; Bulger, P.G *Angew. Chem. Int. Ed.* **2006**, *45*, 7134. (d) Pelliser, H. *Tetrahedron* **2006**, *4*, 2076. (e) Kirsch, S.F. *Synthesis* **2008**, *20*, 3183.
2. (a) Tietze, L. F. *Chem. Rev.* **1996**, *96*, 115. (b) Tietze, L. F.; Beifuss, U. *Angew. Chem. Int. Ed.* **1993**, *32*, 131. (c) Tietze, L. F.; Lieb, M. *Curr. Opin. Chem. Biol.* **1998**, *2*, 363. (d) Tietze L. F.; Modi, A. *Med. Res. Rev.* **2000**, *20*, 304. (e) Tietze, L. F. Brasche, G.; Gericke, G. *Domino Reactions in Organic Synthesis*, Wiley-VCH:Weinheim, 2006.
3. (a) Parsons, P. J.; Penkett, C. S.; Shell, A. J. *Chem. Rev.* **1996**, *96*, 195. (b) Ho, T. L. *Tandem Reactions in Organic Synthesis*, Wiely Interscience, New York, 1997. (c) Taylor, R. J. K.; Reid, M. F.; Raw, R. A. *Acc. Chem. Res.* **2005**, *48*, 851.
4. (a) Schobert, R.; Gordon, G. J. *Curr. Org. Chem.* **2002**, *6*, 1181. (b) Taylor, R. J. K.; Quesada, E. *Synthesis* **2005**, *19*, 3193.
5. (a) Majik, M. S.; Parameswaran, P. S.; Tilve, S. G. *J. Org. Chem.* **2009**, *74*, 3591. (b) Patre, R. E.; Gawas, S.; Parameswaran, P. S; Tilve, S. G. *Tetrahedron Lett.* **2007**, *48*, 3517. (c) Desai, V. G.; Manekar-Tilve, A. S.; Tilve, S. G. *Synth. Commun.* **1996**, *29*, 3017. (d) Shet, J. B.; Desai, V. G.; Tilve, S. G. *Synthesis* **2004**, *11*, 1859. (e) Desai, V. G.; Mali, R. S.; Tilve, S. G. *J. Chem. Res.* **2000**, *8*, 0150.
6. O'Kennedy, R.; Thornes, R. D. *Coumarins: Biology, Applications and Mode of Action*, Wiley & Sons, Chichester, 1997.
7. Murray, R. D. *Natural Coumarin: Occurrence, Chemistry and Biochemistry* John Wiley & Sons, 1982.
8. Reisch, J.; Szendrei, K.; Minker, K. E.; Novak, I. *Experientia* **1968**, *24*, 992.
9. Burke, B. A.; Parkins, H. *Phytochemistry* **1979**, *18*, 1073.
- 10.(a) Prakash, D.; Lakshmi, V.; Raj, K.. Kapil, R. S. *Fitoterapia* **1989**, *60*, 347. (b) Ito, C. Itoigawa, M.; Ju-ichi, M.; Sakamoto, N.; Tokuda, H.; Nishino, H.; Furukawa, H. *Plant Medica* **2005**, *71*, 84.
- 11.(a) Massanet, G. M.; Pando, E.; Rodriguez-Luis, F.; Salva, *Heterocycles* **1987**, *26*, 154. (b) Massanet, G. M.; Pando, E.; Rodriguez-Luis, F.; Salva, *Heterocycles* **1988**, *27*, 775. (c) Cairns, N.; Harwood, L. M.; Astle, D. P. *J. Chem. Soc. Perkin Trans 1* **1994**, 3101.
- 12.Nicolaou, K. C.; Lister, T.; Denton, R. M.; Gelin, C. F. *Angew. Chem. Int. Ed.* **2007**, *46*, 7501.
- 13.(a) **Procedure for the synthesis of 2,4-diprenyloxybenzaldehyde (4):**
To the mixture of resorcyraldehyde (2.00 g, 14.50 mmol) and potassium carbonate (5.00 g, 36.23 mmol) in acetone (40 mL), prenylbromide (5.20 g, 36.23 mmol) was added slowly in portions. The reaction mixture was refluxed for 12h. It was then cooled, filtered and acetone was removed under vacuum. To this, water (20 mL) was added and extracted with diethyl ether (3 X 20 mL). The

combined organic layer was washed with 2N sodium hydroxide (2 X 15 mL) and then with water (2 X 15 mL). The organic layer was dried over anhydrous sodium sulphate. Evaporation of solvent under reduced pressure gave viscous liquid, which was purified over silica gel column chromatography (EtOAc:hexanes = 1:99) to afford 3.30 g (82.50%) of 2,4-diprenyloxybenzaldehyde **4** as a yellow oil; IR (KBr) 1675 (CO) cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 1.77 (6H, s), 1.81 (6H, s), 4.59 (4H, m), 5.50 (2H, m), 6.48 (1H, s), 6.55 (1H, d, J = 8.7 Hz), 7.81 (1H, d, J = 8.7 Hz), 10.30 (1H, s); ^{13}C -NMR (CDCl_3 , 75 MHz) δ 18.19, 18.23, 25.70, 25.75, 65.14, 65.43, 99.65, 106.43, 118.81, 118.90, 119.23, 130.18, 138.81, 139.01, 163.04, 165.33, 188.39. HRMS m/z [M+Na] $^+$ 297.1460 (calcd for $\text{C}_{17}\text{H}_{22}\text{O}_3\text{Na}$, 297.1467).

(b) Cascade Wittig reaction, double Claisen, Cope rearrangements of 2,4-diprenyloxybenzaldehyde **4 in diphenyl ether for 4h.**

A solution of 2,4-diprenyloxybenzaldehyde **4** (0.20 g, 0.73 mmol) and phosphorane **5** (0.38 g, 1.1 mmol) in diphenyl ether was refluxed for 4h. The reaction mixture was loaded over silica gel column. Using hexanes, diphenyl ether was removed. Further purified by flash chromatography using ethyl acetate and hexanes (9:1) as eluent. Initial fraction gave 3-(3-methylbut-2-enyl)-7-(3-methylbut-2-enyloxy) coumarin (**9**), second fraction gave 8,9,9-trimethyl-6-(3-methylbut-2-enyl)-8,9-dihydro-2*H*-furo[2,3-*h*]chromen-2-one (**10**), third fraction gave 6,8-diprenylumbelliferone (**3**), fourth fraction gave balsamiferone (**2**), fifth fraction gave gravelliferone (**1**) and latter fraction gave demethylsuberosin (**11**).

3-(3-methylbut-2-enyl)-7-(3-methylbut-2-enyloxy) coumarin (9**):** Yield: 5.4 mg (2.5%); gummy mass; IR (KBr) 1725 (CO) cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 1.70 (3H, s), 1.78 (3H, s), 1.82 (6H, s), 3.24 (2H, d, J = 6.9 Hz), 4.57 (2H, d, J = 6.9 Hz), 5.32 (1H, m), 5.49 (1H, m), 6.85 (2H, m), 7.33 (1H, d, J = 9.0 Hz), 7.40 (1H, s); ^{13}C NMR (75 MHz, CDCl_3) δ 17.82, 18.27, 25.80, 28.67, 65.33, 100.00, 101.20, 112.93, 113.19, 118.83, 119.48, 120.00, 125.22, 128.00, 135.36, 138.14, 139.00, 162.90; HRMS m/z [M+H] $^+$ 299.1637 (calcd for $\text{C}_{19}\text{H}_{23}\text{O}_3$, 299.1647).

8,9,9-trimethyl-6-(3-methylbut-2-enyl)-8,9-dihydro-2*H*-furo[2,3-*h*]chromen-2-one (10**):** Yield: 33 mg (15%); white solid; mp 136-137 °C: Lit.¹¹ 136-139 °C; IR (KBr) 1725 (CO) cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 1.42 (3H, d, J = 6.6 Hz), 1.57 (3H, s), 1.58 (3H, s), 1.71 (3H, s), 1.77 (3H, s), 3.29 (2H, d, J = 7.2 Hz), 5.29 (1H, m), 4.50 (1H, q, J = 6.6 Hz), 6.17 (1H, d, J = 9.3 Hz), 7.00 (1H, s), 7.60 (1H, d, J = 9.3 Hz); ^{13}C NMR (75 MHz, CDCl_3): δ 14.16, 17.71, 20.97, 25.33, 25.68, 27.16, 44.38, 111.66, 113.09, 120.99, 121.25, 121.80, 127.33, 133.58, 144.27, 150.04, 160.32; HRMS m/z [M+H] $^+$ 299.1645 (calcd for $\text{C}_{19}\text{H}_{23}\text{O}_3$, 299.1647).

6,8-diprenylumbelliferone (3**):** Yield: 33 mg (15%); white solid; mp 134-136 °C; IR (KBr) 3420 (OH) and 1725 (CO) cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 1.78 (6H, s), 1.81 (3H, s), 1.88 (3H, s), 3.37 (2H, d, J = 6.9 Hz), 3.63 (2H, d, J = 6.9 Hz), 5.30 (2H, m), 6.11 (1H, s), 6.24 (1H, d, J = 9.3 Hz), 7.09 (1H, s), 7.61 (1H, d, J = 9.3 Hz); ^{13}C NMR (75 MHz, CDCl_3): δ 17.87, 22.26, 25.81, 28.88, 112.32, 112.54, 114.49, 120.46, 121.06, 124.81, 125.92, 135.16, 135.89, 144.02, 151.06, 156.57, 161.55. HRMS m/z [M+Na] $^+$ 321.1457 (calcd for $\text{C}_{19}\text{H}_{22}\text{O}_3\text{Na}$, 321.1467).

Balsamiferone (2**):** Yield: 11 mg, (5%); white solid; mp 135-136 °C: Lit.¹¹ 134-136 °C; IR (KBr) 3420 (OH) and 1725 (CO) cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 1.71 (3H, s), 1.76 (3H, s), δ 1.80 (3H, s), 1.81 (3H, s), 3.23 (2H, d, J = 6.9 Hz), 3.39 (2H, d, J = 6.9 Hz), 5.30 (2H, m), 6.99 (1H, s), 7.16 (1H, s), 7.41 (1H, s); ^{13}C NMR (75 MHz, CDCl_3): δ 17.62, 25.82, 28.46, 102.75, 112.97,

119.53, 121.00, 124.55, 125.39, 127.63, 134.70, 135.33, 139.00, 155.82, 157.28, 163.22; HRMS m/z [M+Na]⁺ 321.1459 (calcd for C₁₉H₂₂O₃Na, 321.1467).

Gravelliferone (1): Yield: 22 mg (10%); white solid; mp 165-166 °C; Lit¹¹ mp 166-167 °C; IR (KBr) 3480 (OH) and 1725 (CO) cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 1.45 (6H, s), 1.78 (3H, s), 1.81 (3H, s), 3.39 (2H, d, *J* = 7.2 Hz), 5.08 (2H, m), 5.32 (1H, t), 6.18 (1H, dd, *J* = 10.8 & 16.8 Hz), 6.54 (1H, brs,), 6.94 (1H, s), 7.19 (1H, s), 7.54 (1H, s). HRMS m/z [M+Na]⁺ 321.1461 (calcd for C₁₉H₂₂O₃Na, 321.1467).

Demethylsuberosin (11): Yield: 33 mg (20%); white solid; mp 134-136 °C; Lit¹¹ 133-135 °C; IR (KBr) 3420 (OH) and 1725 (CO) cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 1.75 (3H, s), 1.79 (3H, s), 3.38 (2H, d, *J* = 7.2 Hz), 5.31 (1H, t, *J* = 7.2 Hz), 6.24 (1H, d, *J* = 9.3 Hz), 7.00 (1H, s), 7.21 (1H, s), 7.67 (1H, d, *J* = 9.3 Hz); ¹³C NMR (75 MHz, CDCl₃); δ 17.83, 25.80, 28.03, 102.77, 111.98, 112.00, 121.25, 126.39, 128.14, 134.27, 144.72, 154.02, 158.88, 162.95. HRMS m/z [M+H]⁺ 231.1022 (calcd for C₁₄H₁₅O₃, 231.1021).

14. (a) Sharma, R. B.; Swarrop, D.; Kapil, R. S. *Indian J. Chem.* **1983**, 22B, 408. (b) Sharma, R. B.; Swarrop D.; Kapil, R. S. *Indian J. Chem.* **1982**, 22B, 105. (c) Mali, R. S. Sandhu, P. K.; Manekar-Tilve, A. *J. Chem. Soc. Chem. Commun.* **1994**, 251.